Pacific Biosciences of California (PACB) Stock Forecast, Price Target & Predictions
PACB Stock Forecast
Pacific Biosciences of California stock forecast is as follows: an average price target of $3.00 (represents a 19.52% upside from PACB’s last price of $2.51) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
PACB Price Target
The average price target for Pacific Biosciences of California (PACB) is $3.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $2.00. This represents a potential 19.52% upside from PACB's last price of $2.51.
PACB Analyst Ratings
According to 9 Wall Street analysts, Pacific Biosciences of California's rating consensus is 'Buy'. The analyst rating breakdown for PACB stock is 0 'Strong Buy' (0.00%), 5 'Buy' (55.56%), 3 'Hold' (33.33%), 1 'Sell' (11.11%), and 0 'Strong Sell' (0.00%).
Pacific Biosciences of California Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 03, 2024 | Tycho Peterson | Jefferies | $4.00 | $1.79 | 123.46% | 59.36% |
| May 13, 2024 | Tejas Savant | Morgan Stanley | $4.00 | $1.98 | 102.53% | 59.36% |
| May 13, 2024 | David Westenberg | Piper Sandler | $2.00 | $1.77 | 12.99% | -20.32% |
| May 10, 2024 | Luke Sergott | Barclays | $2.00 | $1.72 | 16.28% | -20.32% |
| Apr 18, 2024 | Matthew Sykes | Goldman Sachs | $2.50 | $1.40 | 78.57% | -0.40% |
| Apr 16, 2024 | Kyle Mikson | Canaccord Genuity | $3.50 | $1.40 | 150.00% | 39.44% |
| Nov 16, 2022 | - | Canaccord Genuity | $14.00 | $10.80 | 29.57% | 457.77% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $7.50 | $7.61 | -1.45% | 198.80% |
| May 15, 2022 | David Westenberg | Piper Sandler | $6.00 | $5.84 | 2.74% | 139.04% |
| Jan 12, 2022 | David Westenberg | Piper Sandler | $20.00 | $14.45 | 38.41% | 696.81% |
The latest Pacific Biosciences of California stock forecast, released on Jun 03, 2024 by Tycho Peterson from Jefferies, set a price target of $4.00, which represents a 123.46% increase from the stock price at the time of the forecast ($1.79), and a 59.36% increase from PACB last price ($2.51).
Pacific Biosciences of California Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 6 |
| Avg Price Target | - | - | $3.00 |
| Last Closing Price | $2.51 | $2.51 | $2.51 |
| Upside/Downside | -100.00% | -100.00% | 19.52% |
In the current month, the average price target of Pacific Biosciences of California stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Pacific Biosciences of California's last price of $2.51. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 28, 2024 | Morgan Stanley | Underperform | Underperform | Hold |
| Aug 28, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Aug 12, 2024 | Morgan Stanley | Buy | Buy | Hold |
| Aug 12, 2024 | Jefferies | Underperform | Underperform | Hold |
| Jun 03, 2024 | Jefferies | - | Buy | Initialise |
| May 13, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| May 13, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| May 10, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Apr 18, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Apr 18, 2024 | Bernstein | Outperform | Outperform | Hold |
Pacific Biosciences of California's last stock rating was published by Morgan Stanley on Aug 28, 2024. The company gave PACB a "Underperform" rating, the same as its previous rate.
Pacific Biosciences of California Financial Forecast
Pacific Biosciences of California Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $55.69M | $47.57M | $38.90M | $27.35M | $32.31M | $35.47M | $33.17M | $36.02M | $34.89M | $30.61M | $29.00M | $27.14M | $19.08M | $17.08M | $15.60M | $27.93M | $21.91M |
| Avg Forecast | $77.20M | $64.70M | $53.90M | $61.90M | $61.28M | $53.59M | $48.73M | $45.58M | $50.32M | $41.95M | $40.88M | $43.44M | $57.47M | $48.76M | $40.18M | $34.38M | $26.20M | $35.40M | $35.16M | $32.91M | $36.12M | $33.60M | $29.99M | $25.58M | $24.79M | $20.33M | $13.72M | $20.07M | $25.49M | $27.04M |
| High Forecast | $77.20M | $64.70M | $53.90M | $61.90M | $61.28M | $53.59M | $48.73M | $45.58M | $50.32M | $45.05M | $40.88M | $43.44M | $59.28M | $50.80M | $40.18M | $34.38M | $26.20M | $35.40M | $35.16M | $32.91M | $36.12M | $33.60M | $29.99M | $25.58M | $24.79M | $20.33M | $13.72M | $20.07M | $25.49M | $27.04M |
| Low Forecast | $77.20M | $64.70M | $53.90M | $61.90M | $61.28M | $53.59M | $48.73M | $45.58M | $50.32M | $39.50M | $40.88M | $43.44M | $54.82M | $47.38M | $40.18M | $34.38M | $26.20M | $35.40M | $35.16M | $32.91M | $36.12M | $33.60M | $29.99M | $25.58M | $24.79M | $20.33M | $13.72M | $20.07M | $25.49M | $27.04M |
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 5 | 9 | 6 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.14% | 1.18% | 1.13% | 1.04% | 0.91% | 1.01% | 1.01% | 1.00% | 1.04% | 1.02% | 1.13% | 1.09% | 0.94% | 1.24% | 0.78% | 1.10% | 0.81% |
Pacific Biosciences of California's average Quarter revenue forecast for Dec 23 based on 5 analysts is $57.47M, with a low forecast of $54.82M, and a high forecast of $59.28M. PACB's average Quarter revenue forecast represents a 3.20% increase compared to the company's last Quarter revenue of $55.69M (Sep 23).
Pacific Biosciences of California EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 5 | 9 | 6 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-64.54M | $-62.27M | $-72.13M | $-76.14M | $-69.03M | $-73.15M | $-78.86M | $-60.97M | $-71.90M | $-35.02M | $-83.25M | $74.41M | $-21.39M | $-20.81M | $3.90M | $3.10M | $-25.90M |
| Avg Forecast | $-77.20M | $-64.70M | $-53.90M | $-61.90M | $-61.28M | $-53.59M | $-48.73M | $-45.58M | $-50.32M | $-41.95M | $-40.88M | $-82.78M | $-57.47M | $-48.76M | $-40.18M | $-75.25M | $-62.28M | $-35.40M | $-35.16M | $-59.49M | $-36.12M | $-33.60M | $-29.99M | $-85.06M | $-24.79M | $-20.33M | $-13.72M | $7.23M | $-25.49M | $-27.04M |
| High Forecast | $-77.20M | $-64.70M | $-53.90M | $-61.90M | $-61.28M | $-53.59M | $-48.73M | $-45.58M | $-50.32M | $-39.50M | $-40.88M | $-66.22M | $-54.82M | $-47.38M | $-40.18M | $-60.20M | $-49.82M | $-35.40M | $-35.16M | $-47.59M | $-36.12M | $-33.60M | $-29.99M | $-68.05M | $-24.79M | $-20.33M | $-13.72M | $8.68M | $-25.49M | $-27.04M |
| Low Forecast | $-77.20M | $-64.70M | $-53.90M | $-61.90M | $-61.28M | $-53.59M | $-48.73M | $-45.58M | $-50.32M | $-45.05M | $-40.88M | $-99.33M | $-59.28M | $-50.80M | $-40.18M | $-90.30M | $-74.73M | $-35.40M | $-35.16M | $-71.38M | $-36.12M | $-33.60M | $-29.99M | $-102.07M | $-24.79M | $-20.33M | $-13.72M | $5.78M | $-25.49M | $-27.04M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.32% | 1.55% | 0.96% | 1.22% | 1.95% | 2.08% | 1.33% | 1.69% | 2.14% | 1.17% | 0.98% | -3.00% | 1.05% | 1.52% | 0.54% | -0.12% | 0.96% |
4 analysts predict PACB's average Quarter EBITDA for Mar 21 to be $-85.06M, with a high of $-68.05M and a low of $-102.07M. This is -214.31% lower than Pacific Biosciences of California's previous annual EBITDA (Dec 20) of $74.41M.
Pacific Biosciences of California Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 5 | 9 | 6 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-66.87M | $-69.83M | $-81.15M | $-79.84M | $-83.60M | $-69.38M | $-84.41M | $-69.33M | $16.54M | $-41.00M | $-87.44M | $74.94M | $-23.71M | $-23.09M | $1.26M | $-91.00K | $-29.12M |
| Avg Forecast | $-40.86M | $-46.31M | $-46.31M | $-46.31M | $-47.86M | $-48.18M | $-48.51M | $-48.96M | $-55.08M | $-59.92M | $-63.46M | $-91.46M | $-78.16M | $-78.80M | $-87.16M | $-83.14M | $-70.81M | $-90.34M | $-92.16M | $-65.72M | $-77.17M | $-60.47M | $-56.11M | $-89.34M | $115.69M | $-36.50M | $-49.03M | $2.34M | $-44.49M | $-40.86M |
| High Forecast | $-40.86M | $-46.31M | $-46.31M | $-46.31M | $-47.86M | $-48.18M | $-48.51M | $-48.96M | $-55.08M | $-47.93M | $-63.46M | $-73.17M | $-65.55M | $-64.03M | $-87.16M | $-66.51M | $-56.65M | $-90.34M | $-92.16M | $-52.58M | $-77.17M | $-60.47M | $-56.11M | $-71.47M | $115.69M | $-36.50M | $-49.03M | $2.81M | $-44.49M | $-40.86M |
| Low Forecast | $-40.86M | $-46.31M | $-46.31M | $-46.31M | $-47.86M | $-48.18M | $-48.51M | $-48.96M | $-55.08M | $-80.89M | $-63.46M | $-109.75M | $-83.20M | $-162.53M | $-87.16M | $-99.77M | $-84.98M | $-90.34M | $-92.16M | $-78.87M | $-77.17M | $-60.47M | $-56.11M | $-107.20M | $115.69M | $-36.50M | $-49.03M | $1.87M | $-44.49M | $-40.86M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.85% | 0.80% | 0.98% | 1.13% | 0.93% | 0.75% | 1.28% | 0.90% | -0.27% | 0.73% | 0.98% | 0.65% | 0.65% | 0.47% | 0.54% | 0.00% | 0.71% |
Pacific Biosciences of California's average Quarter net income forecast for Dec 21 is $-77.17M, with a range of $-77.17M to $-77.17M. PACB's average Quarter net income forecast represents a -566.54% decrease compared to the company's last Quarter net income of $16.54M (Sep 21).
Pacific Biosciences of California SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 5 | 9 | 6 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $43.43M | $40.57M | $39.82M | $45.00M | $36.80M | $39.25M | $39.80M | $37.32M | $31.61M | $29.06M | $26.14M | $17.95M | $14.77M | $15.13M | $24.95M | $16.58M | $20.07M |
| Avg Forecast | $73.70M | $61.77M | $51.46M | $59.10M | $58.50M | $51.16M | $46.52M | $43.51M | $48.04M | $40.05M | $39.03M | $41.47M | $54.87M | $46.56M | $38.36M | $32.82M | $25.02M | $33.80M | $33.57M | $32.10M | $34.48M | $32.08M | $28.63M | $24.42M | $23.66M | $19.41M | $13.10M | $19.16M | $24.33M | $25.81M |
| High Forecast | $73.70M | $61.77M | $51.46M | $59.10M | $58.50M | $51.16M | $46.52M | $43.51M | $48.04M | $43.01M | $39.03M | $41.47M | $56.59M | $48.50M | $38.36M | $32.82M | $25.02M | $33.80M | $33.57M | $38.52M | $34.48M | $32.08M | $28.63M | $24.42M | $23.66M | $19.41M | $13.10M | $19.16M | $24.33M | $25.81M |
| Low Forecast | $73.70M | $61.77M | $51.46M | $59.10M | $58.50M | $51.16M | $46.52M | $43.51M | $48.04M | $37.71M | $39.03M | $41.47M | $52.33M | $45.24M | $38.36M | $32.82M | $25.02M | $33.80M | $33.57M | $25.68M | $34.48M | $32.08M | $28.63M | $24.42M | $23.66M | $19.41M | $13.10M | $19.16M | $24.33M | $25.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 1.06% | 1.21% | 1.80% | 1.09% | 1.17% | 1.24% | 1.08% | 0.99% | 1.01% | 1.07% | 0.76% | 0.76% | 1.15% | 1.30% | 0.68% | 0.78% |
Pacific Biosciences of California's average Quarter SG&A projection for Dec 23 is $54.87M, based on 5 Wall Street analysts, with a range of $52.33M to $56.59M. The forecast indicates a 26.34% rise compared to PACB last annual SG&A of $43.43M (Sep 23).
Pacific Biosciences of California EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 5 | 9 | 6 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.26 | $-0.28 | $-0.34 | $-0.35 | $-0.37 | $-0.31 | $-0.38 | $-0.31 | $0.08 | $-0.21 | $-0.45 | $0.40 | $-0.14 | $-0.15 | $0.01 | $-0.00 | $-0.19 |
| Avg Forecast | $-0.15 | $-0.17 | $-0.17 | $-0.17 | $-0.18 | $-0.18 | $-0.18 | $-0.18 | $-0.20 | $-0.22 | $-0.23 | $-0.28 | $-0.29 | $-0.29 | $-0.32 | $-0.33 | $-0.36 | $-0.33 | $-0.34 | $-0.32 | $-0.28 | $-0.22 | $-0.21 | $-0.46 | $0.42 | $-0.13 | $-0.18 | $-0.16 | $-0.16 | $-0.15 |
| High Forecast | $-0.15 | $-0.17 | $-0.17 | $-0.17 | $-0.18 | $-0.18 | $-0.18 | $-0.18 | $-0.20 | $-0.18 | $-0.23 | $-0.28 | $-0.24 | $-0.24 | $-0.32 | $-0.33 | $-0.36 | $-0.33 | $-0.34 | $-0.32 | $-0.28 | $-0.22 | $-0.21 | $-0.46 | $0.42 | $-0.13 | $-0.18 | $-0.16 | $-0.16 | $-0.15 |
| Low Forecast | $-0.15 | $-0.17 | $-0.17 | $-0.17 | $-0.18 | $-0.18 | $-0.18 | $-0.18 | $-0.20 | $-0.30 | $-0.23 | $-0.28 | $-0.31 | $-0.60 | $-0.32 | $-0.33 | $-0.36 | $-0.33 | $-0.34 | $-0.32 | $-0.28 | $-0.22 | $-0.21 | $-0.46 | $0.42 | $-0.13 | $-0.18 | $-0.16 | $-0.16 | $-0.15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 0.88% | 1.02% | 0.97% | 1.12% | 0.92% | 1.19% | 1.09% | -0.36% | 1.02% | 0.98% | 0.94% | 1.04% | 0.83% | -0.06% | 0.00% | 1.27% |
According to 4 Wall Street analysts, Pacific Biosciences of California's projected average Quarter EPS for Dec 21 is $-0.28, with a low estimate of $-0.28 and a high estimate of $-0.28. This represents a -454.16% decrease compared to PACB previous annual EPS of $0.08 (Sep 21).
Pacific Biosciences of California Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics | $15.14 | $118.84 | 684.94% | Buy |
| EDIT | Editas Medicine | $2.88 | $13.50 | 368.75% | Buy |
| CRSP | CRISPR Therapeutics | $50.59 | $109.58 | 116.60% | Buy |
| PACB | Pacific Biosciences of California | $2.51 | $3.00 | 19.52% | Buy |
| TWST | Twist Bioscience | $42.05 | $42.40 | 0.83% | Buy |
PACB Forecast FAQ
Is Pacific Biosciences of California a good buy?
Yes, according to 9 Wall Street analysts, Pacific Biosciences of California (PACB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 55.56% of PACB's total ratings.
What is PACB's price target?
Pacific Biosciences of California (PACB) average price target is $3 with a range of $2 to $4, implying a 19.52% from its last price of $2.51. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Pacific Biosciences of California stock go up soon?
According to Wall Street analysts' prediction for PACB stock, the company can go up by 19.52% (from the last price of $2.51 to the average price target of $3), up by 59.36% based on the highest stock price target, and down by -20.32% based on the lowest stock price target.
Can Pacific Biosciences of California stock reach $4?
PACB's average twelve months analyst stock price target of $3 does not support the claim that Pacific Biosciences of California can reach $4 in the near future.
What are Pacific Biosciences of California's analysts' financial forecasts?
Pacific Biosciences of California's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $209.17M (high $209.17M, low $209.17M), average EBITDA is $-209M (high $-209M, low $-209M), average net income is $-194M (high $-194M, low $-194M), average SG&A $199.7M (high $199.7M, low $199.7M), and average EPS is $-0.71 (high $-0.71, low $-0.71). PACB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $257.7M (high $257.7M, low $257.7M), average EBITDA is $-258M (high $-258M, low $-258M), average net income is $-180M (high $-180M, low $-180M), average SG&A $246.03M (high $246.03M, low $246.03M), and average EPS is $-0.66 (high $-0.66, low $-0.66).
Did the PACB's actual financial results beat the analysts' financial forecasts?
Based on Pacific Biosciences of California's last annual report (Dec 2022), the company's revenue was $128.3M, which missed the average analysts forecast of $129.68M by -1.06%. Apple's EBITDA was $-297M, beating the average prediction of $-192M by 54.52%. The company's net income was $-297M, missing the average estimation of $-319M by -6.93%. Apple's SG&A was $160.85M, beating the average forecast of $124.48M by 29.22%. Lastly, the company's EPS was $-1.32, missing the average prediction of $-1.35 by -2.25%. In terms of the last quarterly report (Sep 2023), Pacific Biosciences of California's revenue was $55.69M, beating the average analysts' forecast of $48.76M by 14.21%. The company's EBITDA was $-64.538M, beating the average prediction of $-48.764M by 32.35%. Pacific Biosciences of California's net income was $-66.869M, missing the average estimation of $-78.801M by -15.14%. The company's SG&A was $43.43M, missing the average forecast of $46.56M by -6.71%. Lastly, the company's EPS was $-0.26, missing the average prediction of $-0.289 by -10.13%